Title
Pulmonary hypertension: evolution of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Permalink
https://escholarship.org/uc/item/8hs15650

Journal
Journal of thoracic disease, 8(Suppl 7)

ISSN
2072-1439

Authors
Anderson, Ryan J
Malhotra, Atul
Kim, Nick H

Publication Date
2016-07-01

DOI
10.21037/jtd.2016.07.33

Peer reviewed
Pulmonary hypertension: evolution of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Ryan J. Anderson¹, Atul Malhotra², Nick H. Kim²

¹Department of Internal Medicine, ²Division of Pulmonary, Critical Care & Sleep Medicine, University of California San Diego, La Jolla, CA, USA

Correspondence to: Nick H. Kim. Division of Pulmonary, Critical Care & Sleep Medicine, University of California San Diego, 9300 Campus Point Drive #7381, La Jolla, CA 92037, USA. Email: h33kim@ucsd.edu.

Submitted Jun 11, 2016. Accepted for publication Jun 11, 2016. doi: 10.21037/jtd.2016.07.33

View this article at: http://dx.doi.org/10.21037/jtd.2016.07.33

On May 16th, 2016, Nick H. Kim, MD [University of California San Diego (UCSD), Division of Pulmonary, Critical Care & Sleep Medicine] delivered his keynote presentation outlining the current state of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). As the title underscores, the lecture is not simply an outline of current therapeutic strategies but is instead a blueprint detailing the historical foundation of the field, ongoing changes in clinical practice and future directions for advancement.

Dr. Kim’s talk begins with a history of the field of pulmonary vascular medicine. This outline spans from the theory of the porous heart described by Galen in the 2nd century, to the more accurate proposal of the pulmonary circulation by Ibn al-Nafis in the 13th century, to the confirmation of the pulmonary capillary network leading to the modern description of the cardiovascular system by Servetus and Harvey 300 years later (1). The earliest pathological description of pulmonary hypertension can be traced back to the German physician Ernst Von Romberg who described “pulmonary vascular sclerosis” in 1891. Several decades later his fellow countryman, Werner Forssman, introduced a new method for the diagnosis of pulmonary hypertension when he performed the first right heart catheterization on himself. This new diagnostic method opened the way for pioneers Andre Cournard and Dickinson Richards to expand our understanding of the pulmonary circulation and pulmonary vascular disease (2). The contributions by Forssman, Cournard and Richards eventually won them the Nobel Prize in Medicine. In the 1950’s, David Dresdale, a trainee of Cournard and Richards, coined the term “primary pulmonary hypertension”—the disease we now refer to as idiopathic PAH.

Through this historical overview Dr. Kim argues that pulmonary hypertension is a relatively young disease which received little attention in the first few decades following its recognition. It was not until the epidemic of primary pulmonary hypertension caused by the appetite suppressant aminorex in 1965 that the condition first received public attention. In 1973, one year after aminorex was removed from the market, the World Health Organization (WHO) formed the 1st symposium on primary pulmonary hypertension in Geneva, Switzerland. In 1982, the first treatment for primary pulmonary hypertension was published in the form of heart-lung transplantation by Norm Shumway and colleagues (3). The first medical therapy was not realized until the Nobel Prize winning work on prostacyclin by Vane, Bergstrom and Samuelson. Even after the beneficial effects of intravenous prostacyclins were first demonstrated in a later publication in 1982, thirteen years passed before epoprostenol was finally approved by the FDA for the treatment of primary pulmonary hypertension (4). Subsequent discoveries in endothelin biology and the nitric oxide pathway enabled the development of additional therapeutic agents (5).

The growth in the number of potential therapeutic targets ushered in multiple clinical trials in pulmonary hypertension. Over the past two decades many new therapies for PAH were studied and later approved starting with intravenous epoprostenol in 1995 (Figure 1) (6). During this same period the research community transitioned from undertaking mainly small, short term, surrogate-endpoint
driven trials including <300 individuals to significantly larger, longer term and event-endpoint driven trials such as Seraphin (N=742), Ambition (N=500), and Griphon (N=1,156). Short-term trials designed to reach a surrogate endpoint (such as improvement in six minute walk distance) are economical and more feasible. Alternatively, long-term, event-endpoint driven trials can offer more robust argument based on morbidity and mortality data (Table 1) (6). These trials, however, require substantially more resources and may make it too difficult for new therapies to be approved for this relatively rare disease.

With regards to the future of PAH Dr. Kim posits that we can continue to help our patients by thinking broadly in the clinic and in the laboratory. He emphasizes that patients commonly do not receive timely or accurate diagnoses and are often not treated by pulmonary hypertension specialists leading to inappropriate or delayed therapy (7). The optimal strategy and timing for initiating medication continues to evolve as do the goals of therapy. Current treatment strategies include initial or early combination medical therapy with an ultimate goal of normalizing right heart function (8). In reviewing current research targets, Dr. Kim is critical of the somewhat narrow focus of available therapies. He recommends that upcoming studies not solely target the three endothelial pathways but expand to investigate interventions targeting other known or emerging pathologic pathways in PAH (9). Additionally, the lack of approved targeted therapies for the largest subgroups of pulmonary hypertension, those in WHO groups 2 and 3, represents a major clinical void and an opportunity for further investigation (10).

For the remainder of his lecture Dr. Kim outlines the past, present and future of CTEPH (11). While a history of an acute pulmonary embolus is a key risk factor for CTEPH, the disease itself is a result of more than residual clot burden. Complex processes including scar formation, inflammation, small vessel disease and right ventricular (RV) dysfunction all contribute to the pathogenesis of CTEPH (12). Furthermore, Dr. Kim emphasizes that CTEPH is not strictly an arterial disease and that patients can develop venous and capillary malformations as well. With regards to RV changes, recent studies have demonstrated that RV afterload may be greater in CTEPH when compared to other forms of pulmonary hypertension with similar degrees of pulmonary vascular resistance (13,14). Therefore, patients with CTEPH may experience relatively greater impairement of RV function than those with PAH. These findings propagate the notion that CTEPH is a unique entity of pulmonary hypertension that requires separate consideration and attention.

Figure 1 Chronologic list of PAH therapies and their dates of FDA approval (6). PAH, pulmonary arterial hypertension; FDA, Food and Drug Administration.

<table>
<thead>
<tr>
<th>Date Approved</th>
<th>Therapy/Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>Epoprostenol, Flolan</td>
</tr>
<tr>
<td>2001</td>
<td>Bosentan, Tracleer</td>
</tr>
<tr>
<td>2002</td>
<td>Treprostinil, Remodulin</td>
</tr>
<tr>
<td>2004</td>
<td>Iloprost, Ventavis</td>
</tr>
<tr>
<td>2005</td>
<td>Treprostinil, i.v.</td>
</tr>
<tr>
<td>2005</td>
<td>Sildenafil, Revatio</td>
</tr>
<tr>
<td>2007</td>
<td>Ambrisentan, Letairis</td>
</tr>
<tr>
<td>2009</td>
<td>Tadalafil, Adcirca</td>
</tr>
<tr>
<td>2009</td>
<td>Treprostinil, Tyvaso</td>
</tr>
<tr>
<td>2010</td>
<td>Epoprostenol, Veletri</td>
</tr>
<tr>
<td>2013</td>
<td>Riociguat, Adempas</td>
</tr>
<tr>
<td>2013</td>
<td>Macitentan, Opsumit</td>
</tr>
<tr>
<td>2013</td>
<td>Selexipag, Uptravi</td>
</tr>
<tr>
<td>2015</td>
<td>Treprostinil, Orenitram</td>
</tr>
</tbody>
</table>

Evolution of PAH Therapy
The scope of therapies available to patients with CTEPH remains limited but is expanding in safety, efficacy and breadth. Pulmonary thromboendarterectomy, or pulmonary endarterectomy, remains the therapy of choice for patients with CTEPH. Safety and efficacy of pulmonary thromboendarterectomy continues to improve at UCSD with in hospital mortality now below 2% (15). Furthermore, it has been found that many co-morbidities of traditional concern such as obesity, advanced age, and severity of pulmonary hypertension are not absolute contraindications for successful surgery. For those who are deemed technically inoperable due to distal chronic thromboembolic disease, Riociguat is the first and only approved medical therapy marking a major advancement in therapeutic options available to patients diagnosed with this serious condition. Riociguat has also been approved for persistent or recurrent pulmonary hypertension after pulmonary thromboendarterectomy (16). Dr. Kim emphasizes that the decision of a patient’s operability is often subjective and requires quality imaging, hemodynamics, consideration of patient factors and an experienced multidisciplinary CTEPH team.

Lastly, in addressing the future of CTEPH therapy, Dr. Kim reviews the emerging technique of balloon pulmonary angioplasty (BPA). Since early reports were published of BPA complication rates as high as 60%, centers in Japan have utilized advanced imaging modalities to refine the technique with greatly improved safety and efficacy. Through dedicated team training and cautious patient selection UCSD has successfully integrated BPA into their CTEPH treatment armamentarium. Dr. Kim emphasizes that all patients should first be evaluated and considered for pulmonary thromboendarterectomy, as this remains the only potential curative treatment. However, based on the early success of BPA procedures from Japan and across other major CTEPH centers around the world, we may see a realignment of BPA in the CTEPH treatment algorithm in the near future (17,18).

In summary, pulmonary hypertension has witnessed major advances in recent years. Not long ago, and within our generation, primary pulmonary hypertension had no effective treatment—now we have 14 FDA approved therapies with more on the horizon. CTEPH, once only treated with major cardiothoracic surgery at limited centers worldwide, now has expanded treatment options with more capable treatment centers emerging around the globe. Dr. Kim paints a picture of pulmonary hypertension as a challenging but treatable disease with a promising future.

**Acknowledgements**

None.

**Footnote**

*Conflicts of Interest:* Dr. Malhotra is PI on NIH RO1 HL085188, K24 HL132105 and co-investigator on R21 HL121794, RO1 HL 119201, RO1 HL081823. As an Officer of the American Thoracic Society, Dr. Malhotra has relinquished all outside personal income since 2012. ResMed, Inc. provided a philanthropic donation to the UC San Diego in support of a sleep center. NH Kim: Consultant—Actelion, Bayer, Merck, SteadyMed; Speaker’s bureau—Actelion, Bayer; Research support—Bellerophon, Eiger, Gilead, Lung Biotechnology; Board member—International CTEPH Association, CTEPH.com. The other author has no conflicts of interest to declare.

### Table 1 Comparison of short term, surrogate endpoint driven versus long-term, event endpoint drive trials for PAH (6)

<table>
<thead>
<tr>
<th>Perspectives on PAH clinical trials [2016]</th>
<th>Short term—event endpoint</th>
<th>Long term—event endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feasibility (rare disease)</td>
<td>Clinically more meaningful/impactful</td>
<td></td>
</tr>
<tr>
<td>Reliance on surrogate</td>
<td>Morbidity/mortality</td>
<td></td>
</tr>
<tr>
<td>More nimble</td>
<td>All in</td>
<td></td>
</tr>
<tr>
<td>Fewer centers/countries</td>
<td>Global endeavor</td>
<td></td>
</tr>
<tr>
<td>Opening to new discovery</td>
<td>Raises the ante perhaps too much?</td>
<td></td>
</tr>
<tr>
<td>Explore potential new indications</td>
<td>Strengthen the case in favor</td>
<td></td>
</tr>
<tr>
<td>Cost: $$</td>
<td>Cost: $$$$$$$$$$$</td>
<td></td>
</tr>
<tr>
<td>Harder to approve?</td>
<td>Regulatory fast-pass?</td>
<td></td>
</tr>
</tbody>
</table>

PAH, pulmonary arterial hypertension.
References
